General Catalyst Group Management, LLC
- SEC CIK
- 0001637946
Holdings, Q2 2026
Positions as of Jun 30, 2026, filed Aug 14, 2026.SEC
- Positions
- 14
- +2 vs. Q1 2026
- Total value
- $188.52M
- +$4.95M (+2.7%) vs. Q1 2026
Compare with Q1 2026: new, added, reduced and sold out
Positions
Long positions only. Changes compare share counts with Q1 2026.
| Security | Class | Shares | Value | % of portfolio | Change in shares | Action | History |
|---|---|---|---|---|---|---|---|
| AVBPARRIVENT BIOPHARMA INC | COM | 1,494,786 | $51.93M | 27.55% | 00.0% | Unchanged | View |
| PBLSPARABILIS MEDICINES INC COM | Stock | 1,600,937 | $43.82M | 23.24% | +1,600,937 | New | View |
| CARTMAPLEBEAR INC | COM | 710,711 | $33.65M | 17.85% | 00.0% | Unchanged | View |
| MAZEMAZE THERAPEUTICS INC | COM | 1,035,910 | $30.91M | 16.40% | 00.0% | Unchanged | View |
| ODTXODYSSEY THERAPEUTICS INC | COMMON STOCK | 810,272 | $15.16M | 8.04% | +810,272 | New | View |
| EIKNEIKON THERAPEUTICS INC | COM | 305,233 | $3.98M | 2.11% | 00.0% | Unchanged | View |
| GUTSFRACTYL HEALTH INC | COM | 4,884,186 | $3.88M | 2.06% | −70.0% | Reduced | View |
| LIFEETHOS TECHNOLOGIES INC | CL A | 74,179 | $1.35M | 0.71% | 00.0% | Unchanged | View |
| CPNGCOUPANG INC | CL A | 54,677 | $949.74K | 0.50% | +18,000+49.1% | Added | View |
| AMZNAMAZON COM INC COM | Stock | 3,882 | $925.24K | 0.49% | +1,300+50.3% | Added | View |
| METAMETA PLATFORMS INC CL A | Stock | 1,320 | $743.54K | 0.39% | +662+100.6% | Added | View |
| DASHDOORDASH INC CL A | Stock | 2,850 | $525.91K | 0.28% | +2,850 | New | View |
| CVNACARVANA CO | CL A | 6,465 | $425.53K | 0.23% | +6,465 | New | View |
| FIGFIGMA INC CLASS A COM STK | Stock | 14,845 | $268.55K | 0.14% | 00.0% | Unchanged | View |
Sold out since Q1 2026 (2)
Positions held at the end of Q1 2026 that are no longer in this filing.
13F filings by quarter
| Quarter | Filed | Positions | Total value | Changes | Filing |
|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 14 | $188.52M | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 12 | $183.56M | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 17, 2026 | 7 | $221.74M | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 14, 2025 | 8 | $3.04B | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 10 | $4.3B | vs. Q1 2025 | SEC |
| Q1 2025 | Apr 16, 2025 | 11 | $887.5M | vs. Q4 2024 | SEC |
| Q4 2024 | Jan 23, 2025 | 11 | $1.14B | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 6, 2024 | 11 | $1.43B | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 11 | $1.16B | vs. Q1 2024 | SEC |
| Q1 2024 | May 10, 2024 | 11 | $1.3B | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 9, 2024 | 10 | $1.27B | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 9, 2023 | 11 | $1.05B | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 8, 2023 | 10 | $1.25B | vs. Q1 2023 | SEC |
| Q1 2023 | Apr 14, 2023 | 10 | $965.03M | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 15, 2023 | 12 | $889M | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 9, 2022 | 15 | $1.09B | vs. Q2 2022 | SEC |
| Q2 2022 | Jul 29, 2022 | 15 | $1.12B | vs. Q1 2022 | SEC |
| Q1 2022 | May 5, 2022 | 15 | $1.76B | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 13 | $2.63B | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 12 | $1.96B | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 16, 2021 | 10 | $2.31B | vs. Q1 2021 | SEC |
| Q1 2021 | May 14, 2021 | 7 | $2.59B | – | SEC |